ASPN ELISA kit
- Known as:
- ASPN Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ASPN-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ASPN ELISA kit
Related genes to: ASPN ELISA kit
- Gene:
- ASPN NIH gene
- Name:
- asporin
- Previous symbol:
- -
- Synonyms:
- FLJ20129, SLRR1C, PLAP-1
- Chromosome:
- 9q22.31
- Locus Type:
- gene with protein product
- Date approved:
- 2001-03-21
- Date modifiied:
- 2017-07-14
Related products to: ASPN ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ASPN ELISA kit
- Source: PubMed
- Accurate risk stratification is essential for guiding treatment decisions and preventing over treatment of prostate cancer, which remains one of the most prevalent cancers among adult men. While the Gleason score, obtained from prostate biopsies, is routinely used to assess tumor aggressiveness, the biopsy procedure carries risks such as pain, infection, and, in some cases, serious complications such as sepsis. In this study, we proposed an artificial intelligence-based framework that integrates mRNA expression profiles with functional interaction networks to classify prostate cancer patients into low-, medium-, and high-risk groups defined by Gleason scores. The pipeline comprised five steps: (1) data collection from The Cancer Genome Atlas (TCGA), (2) preprocessing of gene expression data, (3) two-stage feature selection to identify informative biomarkers, (4) risk classification using a dual-branch graph neural network (GNN) that combines gene-gene interaction graphs with sample-level expression features, and (5) model interpretation using SHAP to quantify feature contributions. Differentially expressed genes were identified in the High (ASPN, GMNN, PEBP4, C2, KNCK17), Medium (C2, IGSF1, ASPN, CDKN3, AMH), and Low (TNMD, VWA5B2, ST6GALNAC5, CYP3A5, PHGR1) risk groups, underscoring the molecular heterogeneity of disease progression. On an independent held-out test set, the model achieved AUCs of 0.86, 0.88, and 0.95 for the low-, medium-, and high-risk groups, respectively, with an overall accuracy of 80%. These results suggest that combining GNN-based modeling with explainable AI can capture both global and local molecular patterns relevant to tumor aggressiveness. However, as the model was developed and evaluated solely on the TCGA cohort, the findings should be regarded as exploratory, and external validation will be required to establish generalizability. Within these limitations, the proposed framework highlights the potential of molecular profiling and graph-based deep learning to support more precise, potentially less invasive, risk assessment and individualized treatment planning in prostate cancer. - Source: PubMed
Publication date: 2026/09/08
Pirmoradi SaeedVaghefi Moghaddam SevilArdalan MohammadrezaSharifi Bonab Mir MohsenTeshnehlab MohammadZununi Vahed Sepideh - Esophagogastric junction adenocarcinoma (EGJA) is an aggressive malignancy of the digestive system with poor prognosis. Early diagnosis and accurate prediction of tumor progression remain major clinical challenges. This study aimed to identify and validate molecular biomarkers and construct a precise diagnostic model, providing a scientific basis for individualized treatment. - Source: PubMed
Publication date: 2026/06/26
Chen YeYuan LiuhongSun HuihuiChen YingLi BoQian MengWang ZhenxiangZhang YanXiong JieLiang QianTao KunTan ZhenyuXu Shuchang - Triaptosis is a recently characterized form of programmed cell death with unclear implications in cancer. This study aimed to investigate the prognostic significance and biological relevance of triaptosis in gastric cancer (GC). - Source: PubMed
Publication date: 2026/09/05
Cui XirongQiu HongkunZhang HailianXu HuijingLiu Mao - Interventional procedures that target the sympathetic nervous system and specific autonomic and sensory ganglia are widely used for refractory visceral, neuropathic, and cancer-related pain. They can provide substantial, often durable analgesia but carry a small yet clinically important risk of serious adverse events. This is the third part of our narrative-review series on the safety of interventional pain procedures, following Part 1 (spinal pain injections) and Part 2 (procedures for back pain), both published in the Journal of Pain Research. It is a structured but non-systematic narrative review (PubMed, Scopus, Embase, and the Cochrane Library; 1980-2026). We examine the complications of image-guided and neuroablative procedures directed at the trigeminal (Gasserian), sphenopalatine, stellate, thoracic sympathetic, celiac/splanchnic, lumbar sympathetic, superior and inferior hypogastric, and impar ganglia and plexuses; we outline the pharmacology of phenol and ethanol and compare them with conventional radiofrequency and cryoneurolysis. Most reported complications are mild, self-limiting, and physiologically predictable, such as hypotension, diarrhea, transient sensory change, and Horner syndrome. Serious events-paraplegia, spinal cord infarction, retropharyngeal hematoma, meningitis, visceral perforation, and anesthesia dolorosa-appear uncommon, but their true incidence remains uncertain and varies by procedure, and much of the evidence derives from isolated case reports. They reflect either anatomical proximity to critical neurovascular structures or unintended spread of the neurolytic agent. Across techniques, the determinants of safety comprise real-time image guidance, meticulous needle placement, incremental dosing, contrast confirmation, attention to anticoagulation status, and careful patient selection. - Source: PubMed
Publication date: 2026/08/17
Lo Bianco GiulianoMarchesini MaurizioNatoli SilviaCosta Carmelo AttilioLi SeanDiwan SudhirDay MilesTinnirello AndreaAbd-Elsayed AlaaPiraccini EmanuelePapa AlfonsoSchatman Michael E